CTChengsen Tian

Chengsen Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chengsen Tian has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Sitao Zhang

    School of Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271000, Shandong. China

    1 shared publication
  • Tingting Liu

    Department of Medicinal Chemistry, School of Pharmacy, State Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong First Medical University, Jinan, Shandong, 250117, China

    1 shared publication
  • Yanzhao Chen

    School of Pharmaceutical Sciences, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian 271000, Shandong. China

    1 shared publication
  • Yichao Wan

    Key Laboratory of Theoretical Organic Chemistry and Functional Molecule, Ministry of Education, School of Chemistry and Chemical Engineering, Hunan University of Science and Technology, Xiangtan, Hunan, 411201, PR China

    1 shared publication
  • Yujing He

    School of Pharmaceutical Sciences & Institute of Materia Medica, National Key Laboratory of Advanced Drug Delivery and Release Systems, Shandong First Medical University & Shandong Academy of Medical Sciences , Jinan 250117

    1 shared publication
  • Zeru Tian

    Department of Biomedical Engineering, Department of Biochemistry, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering University of Texas Southwestern Medical Center Dallas Texas USA

    1 shared publication

Latest Publications

  • Dual-target Inhibitors Based on BRD4: Novel Therapeutic Approaches for Cancer

    by Sitao Zhang, Yanzhao Chen, Chengsen Tian, Yujing He, Zeru Tian, Yichao Wan, Tingting Liu

    Background: Currently, cancer continues being a dramatically increasing and serious threat to public health. Although many anti-tumor agents have been developed in recent years, the survival rate of patients is not satisfactory. The poor prognosis of cancer patients is closely related to the occurrence of drug resistance. Therefore, it is urgent to develop new strategies for cancer treatment. Multi-target therapies aim to have additive or synergistic effects and reduce the potential for the development of resistance by integrating different pharmacophores into a single drug molecule. Given the fact that majority of diseases are multifactorial in nature, multi-target therapies are being exploited with increasing intensity, which has brought improved outcomes in disease models and obtained several compounds that have entered clinical trials. Thus, it is potential to utilize this strategy for the treatment of BRD4 related cancers. This review focuses on the recent research advances of dual-target inhibitors based on BRD4 in the aspect of anti-tumor. Methods: We have searched the recent literatures about BRD4 inhibitors from the online resources and databases, such as pubmed, elsevier and google scholar. Results: In the recent years, many efforts have been taken to develop dual-target inhibitors based on BRD4 as anti-cancer agents, such as HDAC/BRD4 dual inhibitors, PLK1/BRD4 dual inhibitors and PI3K/BRD4 dual inhibitors and so on. Most compounds display good anti-tumor activities. Conclusion: Developing new anti-cancer agents with new scaffolds and high efficiency is a big challenge for researchers. Dual-target inhibitors based on BRD4 are a class of important bioactive compounds. Making structural modifications on the active dual-target inhibitors according to the corresponding structure-activity relationships is of benefit to obtain more potent anti-cancer leads or clinical drugs. This review will be useful for further development of new dual-target inhibitors based on BRD4 as anti-cancer agents.